 |
|
|
| |
A Phase 3 Double-Blind Placebo-Controlled Evaluation of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Genotype 1, 2, 4, 5, 6 HCV-Infected Patients:
Results of the ASTRAL-1 Study
|
| |
| |
Reported by Jules Levin
AASLD Nov 13-17 San Francisco
Jordan J. Feld1, Kosh Agarwal2, Christophe Hezode3, Tarik Asselah4, Peter J. Ruane5, Norbert Gruener6, Armand Abergel7, Alessandra Mangia8, Ching-Lung Lai9, Henry Lik-Yuen Chan10, Francesco Mazzotta11, Christophe Moreno12, Eric M. Yoshida13, Stephen Shafran14, William J. Towner15, Tram T. Tran16, Yanni Zhu17, Evguenia S. Svarovskaia17, John McNally17, Anu Osinusi17, Diana M. Brainard17, John G. McHutchison17, Ira M. Jacobson18, Stefan Zeuzem19
1Toronto Western Hospital, Ontario, Canada; 2King's College Hospital Foundation Trust, London, UK; 3Universite Paris-Est, Creteil, France; 4University Paris Diderot, Clichy, France; 5Ruane Medical and Liver Health Institute, Los Angeles, CA; 6Ludwig-Maximilians-University, Munich, Germany; 7Universite d'Auvergne, Clermont-Ferrand, France; 8Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy; 9University of Hong Kong; 10The Chinese University of Hong Kong; 11Maria Annunziata Hospital, Florence, Italy; 12Hôpital Erasme, Universite Libre de Bruxelles, Brussels, Belgium; 13University of British Columbia, Vancouver, Canada; 14University of Alberta, Edmonton, Canada; 15Southern California Permanente Medical Group, Los Angeles, CA; 16Cedars-Sinai Medical Center, Los Angeles, CA; 17Gilead Sciences, Inc., Foster City, CA; 18Mount Sinai Beth Israel Medical Center, NY; 19JW Goethe University Medical Center, Frankfurt, Germany
|
| |
|
|
|
|
|
